1,272
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study

, , , , , , , , , , , , , , , , , , , ORCID Icon, , ORCID Icon, , & ORCID Icon show all
Pages 1454-1462 | Received 03 Feb 2022, Accepted 26 Jun 2022, Published online: 12 Jul 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Marisa Iborra, Rocio Ferreiro-Iglesias, Martín-Arranz Maria Dolores, Francisco Mesonero Gismero, Alejandro Mínguez, Sol Porto-Silva, Laura García-Ramírez, Irene García de la Filia, Mariam Aguas, Laura Nieto-García, Cristina Suárez Ferrer, Guillermo Bastida, Manuel Barreiro-De-Acosta & Pilar Nos. (2024) Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort. Scandinavian Journal of Gastroenterology 59:3, pages 260-268.
Read now
Jurij Hanzel, Christopher Ma & Vipul Jairath. (2023) Mirikizumab for the Treatment of Moderate to Severe Ulcerative Colitis. Immunotherapy 15:15, pages 1199-1208.
Read now
Klaus R. Herrlinger & Eduard F. Stange. (2023) Prioritization in inflammatory bowel disease therapy. Expert Review of Gastroenterology & Hepatology 17:8, pages 753-767.
Read now
Sophie Vieujean, Edouard Louis, Silvio Danese & Laurent Peyrin-Biroulet. (2023) A critical review of ustekinumab for the treatment of active ulcerative colitis in adults. Expert Review of Gastroenterology & Hepatology 17:5, pages 413-430.
Read now

Articles from other publishers (5)

Tsz Hong Yiu, Yanna Ko, Aviv Pudipeddi, Patrizia Natale & Rupert W. Leong. (2024) Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics.
Crossref
Hu Zhang, Chenlu Mu, Yu Gu, Fanyi Meng, Xiali Qin & Hailong Cao. (2024) Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis. Pharmacological Research 202, pages 107108.
Crossref
Parambir S. Dulai, Siddharth Singh, Vipul Jairath, Emily Wong & Neeraj Narula. (2024) Integrating Evidence to Guide Use of Biologics and Small Molecules for Inflammatory Bowel Diseases. Gastroenterology 166:3, pages 396-408.e2.
Crossref
Gursimran S. Kochhar, Aakash Desai, Francis A. Farraye, Raymond K. Cross, Sandra El‐Hachem, Parambir S. Dulai & Miguel Regueiro. (2023) Efficacy of biologic and small molecule agents as second‐line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity‐matched cohort study. Alimentary Pharmacology & Therapeutics 58:3, pages 297-308.
Crossref
Amneet Hans, Robert Battat & Dana J. Lukin. (2022) Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. Current Gastroenterology Reports 24:12, pages 157-170.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.